Squarepoint’s Theriva Biologics TOVX Stock Holding History

Squarepoint’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10	Closed	-$85K	–	2339
2017 Q3	$85K	Buy	10 +2	+25%	+$11.6K	﹤0.01%	1524
2017 Q2	$40K	Buy	8 +7	+700%	+$34.9K	﹤0.01%	1467
2017 Q1	$8K	Sell	1 -4	-80%	-$27.9K	﹤0.01%	1476
2016 Q4	$35K	Buy	+5	New	+$51.3K	﹤0.01%	1712

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint's TOVX Position: Q4 2017 in Review

Squarepoint sold out of Theriva Biologics (TOVX) in Q4 2017, closing a stake of 10 shares — an estimated $85K sold.

Squarepoint first reported a position in TOVX in Q4 2016 and held it in 4 quarters. The position peaked at $85K in Q3 2017. 48 funds tracked by Wall St. Rank hold TOVX as of Q4 2017.

Squarepoint reported no remaining Theriva Biologics position as of Q4 2017 after selling out during the quarter.
Squarepoint sold 10 Theriva Biologics shares in Q4 2017, an estimated $85K.
Squarepoint first reported a position in Theriva Biologics in Q4 2016 and held it in 4 quarters.
Squarepoint's Theriva Biologics position peaked at $85K in Q3 2017.
48 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2017.

Based on Squarepoint's 13F filing for Q4 2017, filed 14 Feb 2018.